Strong product pipeline, valuations keep street positive on Aurobindo

The company delivered a muted show in the September quarter

The Aurobindo Pharma stock gained 3.5 per cent in trade on Wednesday despite a muted performance in the September quarter. Most analysts shrugged off the miss on operating performance and instead focused on the recovery in the US business in Q2 and the revenue visibility in that market.

Overall, the revenue was down 2 per cent, while the operating profit margin slipped 210 basis points over the year-ago quarter.

What pegged back the sales in the September quarter was the performance of the antiretroviral (ARV) segment, which reported a 71 per cent YoY decline in the revenue on a higher base. Higher